Emtricitabine
- Generic Name
- Emtricitabine
- Brand Names
- Atripla, Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Truvada
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10FN3O3S
- CAS Number
- 143491-57-0
- Unique Ingredient Identifier
- G70B4ETF4S
- Background
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of ...
- Indication
Emtricitabine is indicated in combination with other medications for the treatment of HIV-1 infections; treatment of HIV-1 infections in pediatric patients 25-35kg, treatment of HIV-1 infections in adult patients ≥35kg, for pre exposure prophylaxis of HIV-1 in adolescent and adult patients excluding those who have receptive vaginal sex; treatment of HIV-1 in...
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Pre-Exposure Prophylaxis (PrEP)
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT02116660
Study to Evaluate a HIV Drug for the Treatment of HIV Infection
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 107
- Registration Number
- NCT01803074
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
- Conditions
- Interventions
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 426
- Registration Number
- NCT01709084
Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 594
- Registration Number
- NCT01505114
- Locations
- 🇺🇸
Weill Cornell Chelsea CRS, New York, New York, United States
🇺🇸New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2024-10-11
- Target Recruit Count
- 262
- Registration Number
- NCT01400412
- Locations
- 🇺🇸
University of Colorado Hospital CRS (6101), Aurora, Colorado, United States
🇺🇸Univ. of South Florida (USF) College of Medicine ATN CRS (33001), Tampa, Florida, United States
🇺🇸Washington U CRS (2101), Saint Louis, Missouri, United States
The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 19
- Registration Number
- NCT01335620
- Locations
- 🇬🇧
Chelsea & Westminster Hospital NHS Trust, London, United Kingdom
🇬🇧Imperial College Healthcare NHS Trust, London, United Kingdom
Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women
- Conditions
- Interventions
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 24
- Registration Number
- NCT00869960
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
- Conditions
- Interventions
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 54
- Registration Number
- NCT00799864
Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT00743340
- Locations
- 🇿🇦
Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa
🇿🇦Themba Lethu Clinic, Helen Joseph Hospital, Westdene, Johannesburg, South Africa
An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 16
- Registration Number
- NCT00642291
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.